Eli Lilly shares lose after negative obesity drug test results 🔎

Eli Lilly's (LLY.US) shares dip over 4.00% following a study published in The Journal of the American Medical Association revealed that patients who stopped using the company’s obesity drug, tirzepatide (marketed as Zepbound), regained weight. The drug initially led to a significant average weight reduction of 20.0% over 36 weeks of therapy. However, those who switched to a placebo after this period saw a 14% weight gain over the following 52 weeks. In contrast, patients who continued the treatment experienced an additional 5.5% weight loss. This peer-reviewed study, which enrolled 670 adults without diabetes but with obesity or overweight, was sponsored by Eli Lilly. The authors of the study acknowledged its limitations, including not adjusting doses post-randomization and not considering the impact of behavioral therapy on maintaining weight reduction.

In a similar vein, a study funded by Novo Nordisk, Eli Lilly's competitor in the weight loss sector, showed that patients using their weight loss drug, semaglutide, regained two-thirds of their lost weight a year after stopping the treatment.

Following an unfavorable report, Eli Lilly's shares are losing over 4.00% today. The stock prices are falling below the lower boundary of the upward channel in which the shares have remained since the beginning of this year. Source: xStation 5

17 October 2025, 4:55 PM

US100 tries to recover🗽Sell-off hits uranium stocks

17 October 2025, 2:15 PM

Zions Bancorp rebound after sharp US regional bank stocks sell-off 📈

17 October 2025, 12:23 PM

DE40: European markets decline due to concerns about the U.S. banking sector

17 October 2025, 8:56 AM

Zions Bancorporation Shares Under Pressure After Loan Write-Down!

stocks

Cookie name	Description
SERVERID
userBranchSymbol	Expiration date 1 day
test_cookie	Expiration date 1 hour
adobe_unique_id	Expiration date 364 days
__hssc	Expiration date 1 hour
SESSID	Expiration date 1 day
__cf_bm	Expiration date 1 hour
intercom-id-iojaybix	Expiration date 270 days
intercom-session-iojaybix	Expiration date 6 days
xtbCookiesSettings	Expiration date 364 days
TS5b68a4e1027
countryIsoCode
xtbLanguageSettings	Expiration date 364 days
userPreviousBranchSymbol	Expiration date 364 days
intercom-device-id-iojaybix	Expiration date 270 days
__cfruid
_cfuvid

Cookie name	Description
_gid	Expiration date 1 day
_gat_UA-98728395-1	Expiration date 1 hour
_gat_UA-121192761-1	Expiration date 1 hour
_gcl_au	Expiration date 89 days
_ga_CBPL72L2EC	Expiration date 729 days
_ga	Expiration date 729 days
__hstc	Expiration date 179 days
__hssrc
_vwo_uuid_v2	Expiration date 365 days
_ga_TC79BEJ20L	Expiration date 729 days
_vwo_uuid	Expiration date 365 days
_vwo_ds	Expiration date 29 days
_vwo_sn	Expiration date 1 hour
_vis_opt_s	Expiration date 99 days
_vis_opt_test_cookie
af_id	Expiration date 394 days
afUserId	Expiration date 730 days
AF_SYNC	Expiration date 6 days
AnalyticsSyncHistory	Expiration date 29 days

Cookie name	Description
MUID	Expiration date 389 days
_omappvp	Expiration date 3998 days
_omappvs	Expiration date 1 hour
_uetsid	Expiration date 1 day
_uetvid	Expiration date 389 days
_fbp	Expiration date 89 days
fr	Expiration date 89 days
_ttp	Expiration date 89 days
_tt_enable_cookie	Expiration date 89 days
hubspotutk	Expiration date 179 days
IDE	Expiration date 389 days
YSC
VISITOR_INFO1_LIVE	Expiration date 179 days
li_sugr	Expiration date 89 days
guest_id_marketing	Expiration date 729 days
guest_id_ads	Expiration date 729 days
guest_id	Expiration date 729 days
muc_ads	Expiration date 729 days
VISITOR_PRIVACY_METADATA	Expiration date 179 days
MSPTC	Expiration date 389 days

Cookie name	Description
bcookie	Expiration date 364 days
lidc	Expiration date 1 day
UserMatchHistory	Expiration date 29 days
bscookie	Expiration date 364 days
li_gc	Expiration date 179 days
personalization_id	Expiration date 729 days

Eli Lilly shares lose after negative obesity drug test results 🔎

Join over 1 700 000 XTB Group Clients from around the world